Preventing stroke: The PRoFESS, ONTARGET, and TRANSCEND trial programs

Journal of Hypertension

Volumn 27, Issue SUPPL. 5, 2009, Pages

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Angiotensin II receptor blocker; Antihypertensive therapy; Hypertension; ONTARGET; PRoFESS; Stroke; Telmisartan; TRANSCEND

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH PROGRAM; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INDUCED HYPOTENSION; KIDNEY DYSFUNCTION; META ANALYSIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; UNCONTROLLED HYPERTENSION;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; FEMALE; HUMANS; MALE; MIDDLE AGED; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 70349406414     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000357906.60778.7f     Document Type: Review

References (20)

1. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 352:1801-1807.
2. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective Studies Collaboration. Lancet 1995; 346:1647-1653.
3. Sacco R.L. Adams R. Albers G. Alberts M.J. Benavente O. Furie K. Goldstein L.B. Gorelick P. Halperin J. Harbaugh R. Johnston S.C. Katzan I. Kelly-Hayes M. Kenton E.J. Marks M. Schwamm L.H. Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke - Co-sponsored by the council on cardiovascular radiology and intervention. The American Academy of Neurology affirms the value of this guideline Stroke 2006 37 2 577-617 DOI 10.1161/01.STR.0000199147.30016.74, PII 0000767020060200000095 3 Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37:577-617. (Pubitemid 43732031)
4. Schrader J. Luders S. Kulschewski A. Hammersen F. Plate K. Berger J. Zidek W. Dominiak P. Diener H.C. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES) Stroke 2005 36 6 1218-1224 DOI 10.1161/01.STR.0000166048.35740.a9 4 Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226. (Pubitemid 40798742)
5. Lithell H. Hansson L. Skoog I. Elmfeldt D. Hofman A. Olofsson B. Trenkwalder P. Zanchetti A. The study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial Journal of Hypertension 2003 21 5 875-886 DOI 10.1097/00004872-200305000-00011 5 Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE) : principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886. (Pubitemid 36677151)
6. Schrader J. Luders S. Kulschewski A. Berger J. Zidek W. Treib J. Einhaupl K. Diener H.C. Dominiak P. The ACCESS study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors Stroke 2003 34 7 1699-1703 DOI 10.1161/01.STR.0000075777.18006.89 6 Schrader J, Luders S, Kulschewski A, Berger J, Zidek VV, Treib J, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34:1699-1703. (Pubitemid 36842630)
7. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis American Journal of Cardiology 2002 89 2 SUPPL. 1 18A-26A PII S0002914901023232 7 Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89:18A-25A. (Pubitemid 34143242)
8. Dahlof B. Devereux R.B. Kjeldsen S.E. Julius S. Beevers G. De Faire U. Fyhrquist F. Ibsen H. Kristiansson K. Lederballe-Pedersen O. Lindholm L.H. Nieminen M.S. Omvik P. Oparil S. Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 2002 359 9311 995-1003 DOI 10.1016/S0140-6736(02)08089-3 8 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
9. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al. Use of ramipril in preventing stroke: double blind randomised trial. SMJ 2002; 324:699-702.
10. Rezaiefar P, Pottie K. Blood pressure and secondary prevention of strokes. How low should we go? Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358:1033-1041.
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. W Engl J Med 2000; 342:145-153.
12. 1 receptor antagonism: The past and future of telmisartan Expert Review of Cardiovascular Therapy 2006 4 5 615-629 http://www.future-drugs.com/ doi/full/10.1586/14779072.4.5.615 DOI 10.1586/14779072.4.5.615 12 Goebel M, Clemenz M, Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev Cardlovasc Ther 2006; 4:615-629. (Pubitemid 44739598)
13. Burnier M. Maillard M. The comparative pharmacology of angiotensin II receptor antagonists Blood Pressure, Supplement 2001 10 1 6-11 13 Burnier M, Maillard M. The comparative pharmacology of angiotensin Il receptor antagonists. Blood Press Suppl 2001; 1:6-11. (Pubitemid 32288980)
14. Fournier A. Messerli F.H. Achard J.M. Fernandez L. Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials Journal of the American College of Cardiology 2004 43 8 1343-1347 DOI 10.1016/j.jacc.2003.10.060, PII S0735109704001421 14 Fournier A, Messerli FH, Achard JM, Fernandez L Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43:1343-1347. (Pubitemid 38496335)
15. Yusuf S, Diener H, Sacco R, Cotton D, Ounpuu S, Lawton VV, et al. Randomized trial of telmisartan therapy to prevent recurrent strokes and major vascular events among 20,332 individuals with recent stroke. N Engl J Med 2008; 359:1225-1237.
16. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. W Engl J Med 2008; 358:1547-1559.
17. Yusuf S, Teo KK, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet2008; 372:11 74-1183. doi:10.1016/S0140- 6736(08)61242-8.
18. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005; 64:817-820.
19. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62:569-573.
20. Weimar C. Roth M.P. Zillessen G. Glahn J. Wimmer M.L.J. Busse O. Haberl R.L. Diener H.-C. Complications following acute ischemic stroke European Neurology 2002 48 3 133-140 DOI 10.1159/000065512 20 Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer ML, Busse O, et al. Complications following acute ischemic stroke. Eur Neurol 2002; 48:133140. (Pubitemid 35316817)